ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
